AskBio Inc. Advances Gene Therapy Clinical Trial for LGMD2I/R9 with Dosing of First Participant in Second Cohort Posted on March 26, 2025March 26, 2025 By admin AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort Post navigation Previous: Connecting for a Cure 2024Next: Atamyo completes the dose-finding study in Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) and obtains US Rare Pediatric Disease Designation for ATA-100 admin Learn More →
